Diffuse Large B-Cell Lymphomas and Burkitt Lymphoma - 15/08/11

Doi : 10.1016/j.hoc.2009.04.004

Laurence de Leval, MD, PhD ^a,^⁎ , Robert Paul Hasserjian, MD ^b
^a Department of Pathology, C.H.U. Sart Tilman, Institute of Pathology, B23, +1, B – 4000-Liège, Belgium
^b Department of Pathology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA

Corresponding author.

Abstract

Diffuse large B-cell lymphomas (DLBCLs) and Burkitt lymphoma (BL) account for the majority of aggressive lymphomas in adults and children. DLBCLs exhibit marked biological heterogeneity and variable clinical presentation and clinical course. Conversely, BL is genetically relatively homogeneous but associated with variable clinicopathological features. In this article, the authors summarize the recent advances pertaining to these B-cell neoplasms, following the latest World Health Organization classification and focusing on changes introduced since the previous edition. These changes include the addition of variants and subgroups of DLBCLs and “borderline” categories for high-grade B-cell neoplasms that show features intermediate between DLBCL and classical Hodgkin lymphoma, or between DLBCL and BL. In particular, the diagnostic and therapeutic problems related to neoplasms with features intermediate between DLBCL and BL will be discussed.

Le texte complet de cet article est disponible en PDF.

Keywords : WHO 2008 classification, Diffuse large B-cell lymphoma, Burkitt, Burkitt-like, High-grade, Pathology, Genetics, Diagnosis